6 unchanged sentences
This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
+Added: Recent Sales of Unregistered Securities
+Added: Purchases of Equity Securities by the Issuer and Affiliated Purchasers
Dividend Policy
3 unchanged sentences
Securities Authorized for Issuance under Equity Compensation Plans
−Removed: The information required by this Item 5 regarding equity compensation plans is incorporated by reference from the information under the captions “Equity Compensation Plan Information” and “Security Ownership of Certain Beneficial Owners and Management” that will be contained in the Proxy Statement.
+Added: The information required by this item with respect to our equity compensation plans is incorporated by reference to our definitive proxy statement relating to our 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates, or the Proxy Statement.
Index to Financial Statements
10 unchanged sentences
Nasdaq Biotechnology Index $100.00 $120.23 $133.14 $144.02 $133.45
−Removed: Recent Sales of Unregistered Securities
Index to Financial Statements
−Removed: Use of Proceeds
−Removed: On January 30, 2020, the U.S.
−Removed: Securities and Exchange Commission declared effective our registration statement on Form S-1 (File No.
−Removed: 333-235806 and File No.
−Removed: 333-236177), as amended, filed in connection with our IPO.
−Removed: There has been no material change in the planned use of proceeds from our IPO from that described in the related prospectus dated January 30, 2020, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended
−Removed: Issuer Purchases of Equity Securities
−Removed: We did not repurchase any of our equity securities during the year ended December 31, 2020.
−Removed: Index to Financial Statements
SELECTED FINANCIAL DATA
25 unchanged sentences
(1) See Notes 2 and 12 to our audited financial statements included elsewhere in this Annual Report on Form 10-K for a description of how we compute basic and diluted net loss per share and the weighted-average number of shares used in the computation of these per share amounts.
+Added: 2021 2020 2019
(in thousands)
3 unchanged sentences
369,447 270,224 101,237
−Removed: 298,269 107,012
+Added: Total assets 408,152 298,269 107,012
Convertible preferred stock — — 166,491
+Added: Long-term debt, net 72,350 — —
Accumulated deficit (408,306) (201,950) (66,272)
−Removed: (201,950) (66,272)
Total stockholders’ equity (deficit) 297,677 270,621 (65,029)
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.